The clinical significance of thrombocytosis in women presenting with a pelvic mass

Chalas, Eva; Welshinger, Marie; Engellener, W.; Chumas, John; Barbieri, Robert L.; Mann, William J.

doi:10.1016/0002-9378(92)91375-k

Cited by 21 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with lung cancer producing bone marrow-stimulating cytokines such as interleukin (IL)-6 [15, 16, 17], IL-1 [15, 17]and macrophage colony-stimulating factor (M-CSF) [18]could exhibit thrombocytosis even at an early stage. Thrombocytosis has been linked with shorter survival in patients with gynecologic cancer [8, 9, 10, 11, 12, 13, 19, 20], renal cancer [8], gastric cancer [14], and lung cancer [6, 7]. Our results confirmed a poor prognosis for lung cancer patients manifesting thrombocytosis.…”

Section: Discussionsupporting

confidence: 81%

“…Thrombocytosis was defined as a platelet count of at least 40 × 10 4 /mm 3 , in agreement with other studies [2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]. Only platelet counts determined before invasive diagnostic procedures obtained at the first visit to our hospital were considered.…”

Section: Methodsmentioning

confidence: 58%

“…In previous reports, the prevalence of thrombocytosis in patients with gynecologic cancer [8, 9, 10, 11, 12, 13], lung cancer [2, 3, 4, 5, 6], colon cancer [2], and gastric cancer [14]were reported as 14–38, 32–46%, 33 and 11%, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, thrombocytosis is frequent in patients with colon cancer [2], lung cancer [2, 3, 4, 5, 6, 7], renal cancer [8], cervical cancer [9, 10, 11], and ovarian cancer [12, 13], with a reported occurrence of 15–40%. However, few reports have assessed correlations of this finding with other clinicopathologic factors, or with survival, in patients with lung cancer.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Thrombocytosis as a Useful Prognostic Indicator in Patients with Lung Cancer

et al. 2004

View full text Add to dashboard Cite

Background: Thrombocytosis can accompany various cancers including lung cancer. This finding has recently been suggested to indicate poor prognosis. Objectives and Methods: We retrospectively examined the clinical records of 611 patients with lung cancer to investigate whether there is a correlation between thrombocytosis, other clinicopathologic factors, and survival Results: Ninety-eight of the patients (16%) manifested thrombocytosis at the time of their first evaluation at our hospital. Thrombocytosis and age (p = 0.0006) and thrombocytosis and performance status (p = 0.0002) are significantly correlated, but thrombocytosis is not related to gender, tumor histology, clinical stage, or serum lactate dehydrogenase concentrations. Survival is significantly shorter in patients with thrombocytosis: [median survival time (MST) 7.5 months; n = 98] than without thrombocytosis (MST 10.1 months; n = 513; p = 0.0029). Multivariate analysis of prognostic factors using the Cox proportional hazards model indicated that thrombocytosis had independent prognostic significance. Conclusion: Thrombocytosis at the first patient evaluation is an independent prognostic factor in lung cancer.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Methodsmentioning

confidence: 58%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Thrombocytosis as a Useful Prognostic Indicator in Patients with Lung Cancer

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Although postoperative residual tumour is a strong predictor for prognosis, 10,11 we demonstrated that it was not the only predictive parameter for survival in advanced EOC. Several other parameters have been suggested to be predictive for survival in advanced ovarian cancer including age, 13 performance status, 29 tumour histology, 30 histological grade, 31 presence of ascites, 14,32 preoperative blood platelets, 33,34 haemoglobin, 32 albumin, 29,35 LDH, 36 and CA125 35-37 serum concentrations. Most of these studies focused on identification of prognostic parameters.…”

Section: Discussionmentioning

confidence: 99%

The prediction of progression‐free and overall survival in women with an advanced stage of epithelial ovarian carcinoma

Gerestein

Eijkemans

Jong

et al. 2009

BJOG

View full text Add to dashboard Cite

Objective Prognosis in women with ovarian cancer mainly depends on International Federation of Gynecology and Obstetrics stage and the ability to perform optimal cytoreductive surgery. Since ovarian cancer has a heterogeneous presentation and clinical course, predicting progression-free survival (PFS) and overall survival (OS) in the individual patient is difficult. The objective of this study was to determine predictors of PFS and OS in women with advanced stage epithelial ovarian cancer (EOC) after primary cytoreductive surgery and first-line platinum-based chemotherapy.Design Retrospective observational study.Setting Two teaching hospitals and one university hospital in the south-western part of the Netherlands.Population Women with advanced stage EOC.Methods All women who underwent primary cytoreductive surgery for advanced stage EOC followed by first-line platinumbased chemotherapy between January 1998 and October 2004 were identified. To investigate independent predictors of PFS and OS, a Cox' proportional hazard model was used. Nomograms were generated with the identified predictive parameters.Main outcome measures The primary outcome measure was OS and the secondary outcome measures were response and PFS.Results A total of 118 women entered the study protocol. Median PFS and OS were 15 and 44 months, respectively. Preoperative platelet count (P = 0.007), and residual disease <1 cm (P = 0.004) predicted PFS with a optimism corrected c-statistic of 0.63. Predictive parameters for OS were preoperative haemoglobin serum concentration (P = 0.012), preoperative platelet counts (P = 0.031) and residual disease <1 cm (P = 0.028) with a optimism corrected c-statistic of 0.67.Conclusion PFS could be predicted by postoperative residual disease and preoperative platelet counts, whereas residual disease, preoperative platelet counts and preoperative haemoglobin serum concentration were predictive for OS. The proposed nomograms need to be externally validated.

show abstract

The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors

Güngör

Kanat-Pektaş

Sucak

et al. 2008

Arch Gynecol Obstet

View full text Add to dashboard Cite

Thrombocytosis is frequently detected in preoperative evaluation of women diagnosed with epithelial ovarian tumors. The data obtained by the previous and present studies suggest that thrombocytosis is associated with factors reflecting a more aggressive tumor biology, and predicting poor survival in women with epithelial ovarian tumors. However, these data are limited by the retrospective nature of the studies and do not confirm a casual relationship between thrombocytosis and tumor behavior. Molecular studies investigating the expression of platelet secretory factors are required to clarify the differences among data provided by the literature.

show abstract

The clinical significance of thrombocytosis in women presenting with a pelvic mass

Cited by 21 publications

References 20 publications

Thrombocytosis as a Useful Prognostic Indicator in Patients with Lung Cancer

Thrombocytosis as a Useful Prognostic Indicator in Patients with Lung Cancer

The prediction of progression‐free and overall survival in women with an advanced stage of epithelial ovarian carcinoma

The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors

Contact Info

Product

Resources

About